Bristol-Myers Squibb Company (NYSE:BMY) Shares Bought by Bollard Group LLC
Bollard Group LLC boosted its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 0.8% during the second quarter, Holdings Channel reports. The fund owned 188,001 shares of the biopharmaceutical company’s stock after buying an additional 1,528 shares during the period. Bristol-Myers Squibb accounts for 0.6% of Bollard Group LLC’s holdings, making the stock its 28th largest position. Bollard Group LLC’s holdings in Bristol-Myers Squibb were worth $10,475,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently modified their holdings of BMY. Ameriprise Financial Inc. raised its position in shares of Bristol-Myers Squibb by 18.7% in the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after buying an additional 2,451,390 shares during the last quarter. Swiss National Bank raised its position in shares of Bristol-Myers Squibb by 27.2% in the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after buying an additional 1,267,900 shares during the last quarter. State Street Corp raised its position in shares of Bristol-Myers Squibb by 1.8% in the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after buying an additional 1,223,457 shares during the last quarter. NN Investment Partners Holdings N.V. raised its position in shares of Bristol-Myers Squibb by 103.1% in the second quarter. NN Investment Partners Holdings N.V. now owns 1,581,454 shares of the biopharmaceutical company’s stock worth $88,119,000 after buying an additional 802,931 shares during the last quarter. Finally, Karp Capital Management Corp purchased a new position in shares of Bristol-Myers Squibb during the first quarter worth $38,890,000. Hedge funds and other institutional investors own 69.79% of the company’s stock.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) traded up 0.25% during mid-day trading on Friday, reaching $56.73. 4,060,530 shares of the company’s stock traded hands. The stock has a market capitalization of $93.03 billion, a PE ratio of 20.72 and a beta of 1.17. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $60.86. The company’s 50-day moving average price is $55.80 and its 200-day moving average price is $54.64.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. The company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.69 EPS. Analysts anticipate that Bristol-Myers Squibb Company will post $2.97 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th were issued a dividend of $0.39 per share. The ex-dividend date was Wednesday, July 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.75%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 56.73%.
COPYRIGHT VIOLATION NOTICE: “Bristol-Myers Squibb Company (NYSE:BMY) Shares Bought by Bollard Group LLC” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/13/bristol-myers-squibb-company-nysebmy-shares-bought-by-bollard-group-llc.html.
BMY has been the subject of a number of research analyst reports. BMO Capital Markets lowered Bristol-Myers Squibb from a “market perform” rating to an “underperform” rating and set a $47.00 price objective for the company. in a research report on Wednesday, May 3rd. Robert W. Baird initiated coverage on Bristol-Myers Squibb in a research report on Tuesday, April 25th. They set an “outperform” rating for the company. Jefferies Group LLC restated a “buy” rating and set a $64.00 price objective on shares of Bristol-Myers Squibb in a research report on Monday, June 5th. Vetr raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 price target for the company in a report on Monday, June 5th. Finally, BidaskClub downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, July 3rd. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Bristol-Myers Squibb presently has a consensus rating of “Buy” and an average target price of $62.12.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II bought 6,000 shares of Bristol-Myers Squibb stock in a transaction on Wednesday, August 2nd. The shares were bought at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the acquisition, the director now directly owns 18,000 shares in the company, valued at $1,006,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.23% of the stock is owned by corporate insiders.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.